Ambroxol Chaperone Therapy to Restore NAGLU Activity in MPS III

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no established treatment for Mucopolysaccharidosis type III (MPS III), a lysosomal storage disease characterized by progressive neurodegeneration due to the deficiency of enzymes involved in heparan sulfate degradation, leading to cellular and neurological dysfunction, with current therapies being ineffective.

Innovation Solution

Administering ambroxol, a pharmacological chaperone, to increase the enzymatic activity of N-acetyl-alpha-glucosaminidase (NAGLU) and enhance autophagy-lysosomal fusion, thereby improving lysosomal function and reducing heparan sulfate levels in patients with MPS III.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used for MPS III, then treatment is provided, but the therapies are ineffective in slowing disease progression

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddisease progression rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by using ambroxol to alter the biochemical parameters within lysosomes, specifically changing the enzymatic environment to enhance NAGLU activity and improve heparan sulfate degradation efficiency, thereby transforming an ineffective treatment state into an effective one

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Ambroxol serves as an intermediary substance that mediates between the defective NAGLU enzyme and the substrate (heparan sulfate), enhancing the enzyme's ability to degrade the substrate without directly replacing the enzyme function

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If enzyme replacement therapy is attempted, then enzyme deficiency is addressed, but the complexity of delivery and stability increases

Engineering Contradiction:

Improveenzyme activityVSAvoidtreatment administration complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs self-service by using ambroxol to enable the patient's own defective NAGLU enzyme to function properly, eliminating the need for external enzyme replacement and its associated administrative complexity

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

Instead of replacing the defective enzyme with a complex therapeutic enzyme preparation, the patent uses ambroxol to create a functional copy of normal enzyme activity by enhancing the existing defective enzyme's performance

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Ambroxol increases NAGLU enzyme activity, enhances autophagy-lysosomal fusion, and decreases heparan sulfate levels, potentially alleviating symptoms and slowing disease progression in MPS III patients.

Implementation Method 1

Administering ambroxol, a pharmacological chaperone, to increase the enzymatic activity of N-acetyl-alpha-glucosaminidase (NAGLU)

Methodology Applied

Scientific EffectPharmacological chaperone: Enzyme

Implementation Method 2

enhances autophagy-lysosomal fusion, thereby improving lysosomal function

Methodology Applied

Scientific EffectAutophagy-lysosomal fusion:

Data Source

PatentUS12364673B2Methods and compositions for treating lysosomal storage disorders: ambroxol as treatment agent for Mucopolysaccharidoses III (Sanfilippo syndrome)

Publication Date: 2025.07.22 LYSOSOMAL & RARE DISORDERS RES & TREATMENT CENT INC

AI summary

Methods for treating MPS III diseases are disclosed. The methods involve administering a therapeutically effective amount of a composition comprising ambroxol to a subject with the disease. Also disclosed are pharmaceuticals suitable for treating MPS III diseases.